InsidersTradesSigma
Track the Niagen Bioscience, Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Niagen Bioscience, Inc. has published 6 insider filings. Market capitalisation: €260.3m. The latest transaction was filed on 8 July 2026 (Attribution). Among the most active insiders: Fried Robert N. All data is openly available.
6
Insider Decl.
n/a
Thresholds
€26,140
1 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Niagen Bioscience, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$12.08.
36Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 4,081 of 29,065 companies
70.6
score / 100
Value58
Quality84
FCF yld5.1%
Earn yld6.7%
EV/EBITDA16.7x
ROE22%
Gross mgn64%
Net mgn13%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 July 2026
Declarations6 total
1,106 shares@ US$2.710.0011% mcap0.9% of flowCommon StockSEC:0001417952-26-000002:0
2,314 shares@ US$2.710.0023% mcap100.0% of flowCommon StockSEC:0002042509-26-000001:0
4,255 shares@ US$2.710.0041% mcap100.0% of flowCommon StockSEC:0001834681-26-000001:0
20,000 shares@ US$2.610.021% mcap50.0% of flowCommon StockSEC:0001417952-26-000001:0
4,464.962 shares@ US$6.8172.1% of flowCommon StockSEC:0001834681-25-000005:0
Canonical exit: 12 Feb 2026 (T+90)
66,667 shares@ US$3.3069.2% of flowCommon StockSEC:0001628280-25-017223:0
6 of 6 declarations
关于 Niagen Bioscience, Inc.
Niagen Bioscience, Inc. (NASDAQ: NAGE) 是一家总部位于美国加利福尼亚州洛杉矶的美国生物科学公司。该公司最初名为 ChromaDex，并于2025年3月19日更名为现名，以反映其向NAD+科学和健康老龄化领域的战略转变。其业务围绕 Niagen® 展开，这是一种烟酰胺核糖 (NR) 的专利形式，是 NAD+ 的前体，该公司将其定位为经过科学验证的细胞代谢和长寿相关应用的成分。Niagen Bioscience 现在将自己定位为一家以科学为主导的公司，结合了知识产权、研究合作和循证产品的商业化。（[investors.niagenbioscience.com](https://investors.niagenbioscience.com/news/news-details/2025/ChromaDex-Evolves-Into-Niagen-Bioscience-Marking-a-New-Era-of-Uncovering-the-Potential-of-NAD-With-Precision-Science/default.aspx?utm_source=openai)） 该公司的模式围绕三项主要活动展开。首先是消费者健康，由其旗舰口服补充剂品牌 Tru Niagen® 领导。其次是成分部门，该部门向第三方制造商供应食品级和药物级 Niagen®，并在制药渠道中供应给授权的 503B 外包机构。第三是分析参考标准和服务业务，这是一项传统业务，该公司目前正通过宣布出售其大部分资产而战略性退出。此次剥离强调了对 NAD+ 科学、知识产权货币化以及长寿领域商业增长的明确关注。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001386570/000138657026000013/cdxc-20251231.htm?utm_source=openai)） 从竞争角度来看，Niagen Bioscience 通过其以科学为基础的品牌、围绕 NR 的广泛专利组合以及广泛的全球研究网络来区分自己。该公司根据主要美国电子商务市场在参考期间的收入数据，将 Tru Niagen 描述为美国领先的 NAD+ 增强口服补充剂。它还旨在通过更高价值的形式（例如 Niagen IV 和注射产品）深化其平台，从而将商业机会扩展到核心补充剂业务之外。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1386570/000138657025000015/pressreleasedatedoctober62.htm?utm_source=openai)） 最近的新闻强调了产品扩展和科学验证。Niagen Bioscience 推出了 Tru Niagen Beauty，并于2026年推出了 Niagen 护肤创新实验室和限量发售的 Niagen NanoCloud™ 外用产品，将 Niagen 成分的故事扩展到护肤领域。该公司还强调了在长新冠、帕金森病和外部研究协议方面的临床和研究里程碑，巩固了其作为将科学信誉转化为商业选择的平台的定位。从地理上看，该集团在美国运营，但通过研究伙伴关系、产品分销和全球合作拥有国际业务。对于投资者而言，该股票结合了消费者健康敞口、健康老龄化理论和纳斯达克上市的科学增长故事。（[investors.niagenbioscience.com](https://investors.niagenbioscience.com/news/news-details/2026/Niagen-Bioscience-Launches-Niagen-Skincare-Innovation-Lab-and-Debuts-Dermatologist-Tested-Niagen-NanoCloud-From-Tru-Niagen-Powered-by-Patented-Niagen/default.aspx?utm_source=openai)）
